ADENOSINE INJECTION

The Defense Logistics Agency awarded a single-line-item delivery order, SPE2DP26F8604, to DMS PHARMACEUTICAL GROUP INC (CAGE 1UNB0) for the procurement of one package of ADENOSINE INJECTION, with a total contract value of $231.45, awarded on August 1, 2026, under the basic contract SPE2DX25D9900. The item, identified by NSN 6505016660343 and NDC code NDC25021-0301-68, is to be delivered by August 3, 2026, to JBER AK 99506, with FOB Destination terms placing all transportation costs and risk of loss on the contractor until receipt at the final destination. The contract follows commercial item acquisition procedures under FAR 52.212-4 and FAR 52.212-5, incorporating standard terms for inspection, acceptance, warranty, and statutory compliance. Inspection and acceptance occur at the delivery point by the government’s authorized representative, based solely on conformance to contract requirements, with no external quality standards or military packaging specifications explicitly mandated, though the item is a pharmaceutical requiring appropriate handling. The contractor is a small business eligible under multiple socioeconomic set-asides, including WOSB, HUBZone, and SDVOSB, though only small business status is confirmed through award. Payment is processed by the Defense Finance and Accounting Service in Columbus, Ohio, under appropriation identifier 97X4930 SCBX0012620S33189, using the payment code SL4701, with invoices submitted to the designated address unless otherwise directed. The contract includes the mandatory clause 52.222-50 on combating human trafficking and references an allowable pharmaceutical substitution under RANK 01 - 63323065190 D-70253. No options, extensions, or additional line items are included, and the contract contains no specified COR, COTR, or detailed packaging, preservation, or labeling standards beyond required identifiers such as CAGE, NDC, and CLIN. The award was made under a non-competitive, small business set-aside, though the specific source selection method (e.g., LPTA) is not